Atripla Articles
New Zealand to fund Gilead's Atripla and Truvada
27 November 2012
Gilead HIV drugs Atripla and Truvada to be listed in New Zealand
13 November 2012
Gilead’s Quad regimen to be HIV market leader in 2020, with over $3 billion sales, says Decision Resources
31 October 2011
AHF lambasts Gilead over HIV drug price hikes
6 April 2011
Setback for Merck & Co as vicriviroc disappoints in Ph III
22 January 2010
Blockbuster status predicted for co-formulation of rilpivirine and Truvada with sales of over $2 billion in the HIV Drug Market by 2018
7 January 2010
US mid-caps Biogen, Forest and Gilead post in-line or better-than-expected three-month results
21 October 2009
Mylan's Matrix gets tentative FDA approval under PEPFAR for generic Atripla HIV Treatment
19 August 2009
Gilead files 2nd patent suit against Teva
15 May 2009
Profit up 22% at Gilead on pipeline strength
27 April 2009
Teva files ANDA on Gilead
7 April 2009
Stock Commentary - New York week to Feb 2, 2009
9 February 2009
Gilead up almost 30% on HIV franchise
27 October 2008
Stock Commentary - New York week to Sept 8, 2008
15 September 2008
Gilead leads in selling Atripla in new countries
11 August 2008
Gilead profits up 9% on HIV franchise sales
28 July 2008
Gilead record sales push revenue up 22%
28 April 2008
India NGOs at war with cancer drug patents
7 April 2008
Stock Commentary - New York week to Jan 28, 2008
4 February 2008
EC approves B-MS/Gilead's Atripla
24 December 2007
Cipla ARV price cut does not appease campaigners
24 December 2007
HIV/AIDS drug Atripla debuts in UK
24 December 2007
Stock Commentary - New York week to Oct 29, 2007
5 November 2007
CHMP recommends approval of Atripla for HIV-1
29 October 2007
Gilead's 3rd-qtr 2007 revenue jumps 41%
29 October 2007
Atripla approved in Canada for HIV-1
22 October 2007
AHF blames drug firms for slow ARV uptake
24 September 2007
India's regulators investigate Cipla pricing claims
3 September 2007
India's Cipla pricing claims disputed
3 September 2007
Stock Commentary - New York week to July 23, 2007
30 July 2007
Gilead's 1st-qtr 2007 net income sky-rockets 55%
30 April 2007
Stock Commentary - New York week to April 23, 2007
30 April 2007
Gilead's share price up on strong 4th-qtr sales
12 February 2007
Gilead's 3rd-qtr losses hit $52M on Corus buy
30 October 2006
Stock Commentary - New York week to Oct 16, 2006
23 October 2006
HIV drug Atripla submitted to EMEA
16 October 2006
B-MS and Gilead Sci sign Atripla accord
9 October 2006
Stock Commentary - New York week to July 24, 2006
24 July 2006
Atripla approved by FDA for use in HIV-1 therapy
17 July 2006
Showing 1-49 of 49 articles
- 1
- US Supreme Court says patent settlement can "sometimes" be illegal
- InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against
- Osteoporosis drug bazedoxifene stops growth of breast cancer cells, even in resistant tumors
- Additional indications in Japan for Roche's Avastin and Astellas' Prograf
- Highlights of EHA meeting: Novartis' Jakavi; Bristol-Myers and AbbVie's elotuzumab; Janssen's ibrutinib
